Kyverna Therapeutics' Stiff Person Syndrome Treatments and AI Investments from Jacob Funds

Jacob Funds, in its Q1 2026 investor letter, highlighted the financial volatility stemming from the Middle East conflict and AI sector disruptions, noting investor focus shifting toward AI winners and losers. The fund's portfolio adjustments include positions in biotech firms like Kyverna Therapeutics, Inc. (NASDAQ:KYTX), targeting innovative immune-resetting therapies for autoimmune diseases. Kyverna, with a one-month return of 25.92% and 177.59% annual gain, operates with a market cap of $602.48 million, while its Stiff Person Syndrome drug—the first potential FDA-approved therapy for the condition—draws attention. Similar strategies at Cabaletta Bio and Cartesian Therapeutics underscore broader autoimmune market potential, including myasthenia gravis and multiple sclerosis. Despite slower-than-expected AI adoption, investor optimism mirrors the late 1990s dot-com boom, with agentic AI integration driving portfolio shifts.

Next-Generation Autoimmune Competition

■Stiff Person Syndrome, a rare neurological condition with no approved treatments, sees meaningful symptom improvement in early trials.

■Platform expansion into larger autoimmune markets positions Kyverna as a high-risk, high-reward opportunity.

■CAR-T programs emerge as a focal point for biotech investors seeking scalable innovations.

AI-Driven Investment Strategies

■Agentic AI adoption bolsters Jacob Funds' 2026 portfolio adjustments.

■Partnerships with firms like Securitize and Kyverna reflect a dual focus on tech and healthcare sectors.

■Dot-com-like innovation waves loom, though AI progress remains gradual.

Kemal Tekin's Note: Emerging markets, particularly in Asia-Pacific, are navigating biotech and AI integration for high-risk, high-reward opportunities. Companies like Kyverna, with FDA-pending therapies, could stabilize both health and financial sectors for regional investors.